600129 Chongqing Taiji Industry
- 26.10
- +0.40+1.56%
About Chongqing Taiji Industry Company
The company was founded in 1972, completed a strategic restructuring in 2021, and became the holding enterprise of the “World Top 500” China Pharmaceutical Group Co., Ltd. As an important part of the Sinopharm Group's modern traditional Chinese medicine sector, the company is committed to inheriting and innovating traditional Chinese medicine and developing modern medicine, mainly through intelligent manufacturing of modern traditional Chinese medicine, and is supplementing it with hemp specialty chemicals. The company is mainly engaged in the production and sale of Chinese and Western medicines, and has a complete pharmaceutical industry chain including pharmaceutical industry, pharmaceutical commerce, and herbal medicine cultivation. The company's main products are agastache zhengqi oral liquid, cefazoxime sodium (iboseling), lofendipine sustained-release tablets (Siweipu), toranisetron hydrochloride injection, Xiaojin tablets, Tianmarin injections, morphine hydrochloride sustained-release tablets (Mifecon), rosiglitazone sodium tablets (Taro), emergency syrup, compound banyan root granules, Tongtian oral solution, sodium chloride injection, sinusitis oral solution, Liuwei Dihuang pills, xanmai orange granules Aromatic gas tablets, Tianjiao, glucose injections, xanliton, digestive enzyme tablets, metoprolol tartrate sustained-release tablets, Xia Sangju granules, cold clean-up granules, Wu Zi Yanzong pills, etc. The company's honors include: “First Prize for National Management Achievements”, No. 1 in the 2017 China Pharmaceutical Top Ten Marketing Cases, and No. 2 in the 2019 China OTC Manufacturing Enterprise Comprehensive Statistics Ranking.
Company Profile
Company Executives
- Name
- Position
- Salary
- min yu
- Chairman, Directors, Deputy Chairman of the Nomination Committee, Deputy Chairman of the Strategy Committee
- --
- qingxin meng
- Directors, Member of the Strategy Committee
- --
- binghua yang
- Directors
- --
- kan wang
- Directors, Member of the Strategy Committee, Audit Committee Member, Deputy Chairman of the Remuneration and Assessment Committee
- --
- xueren cheng
- Directors
- --
- bo lai
- Directors, Member of the Remuneration and Assessment Committee
- --
- dongji zhao
- Directors
- --
- tong chen
- Directors
- --
- hongtao he
- Independent Directors, Chairman of the Nomination Committee, Member of the Remuneration and Assessment Committee
- 160.00K
- xian wu
- Independent Directors, Nomination Committee Members, Member of the Strategy Committee, Chairman of the Remuneration and Assessment Committee
- 106.70K
- ling shen
- Independent Directors, Chairman of the Audit Committee, Member of the Remuneration and Assessment Committee
- 160.00K
- shaoxi xiong
- Independent Directors, Audit Committee Member, Nomination Committee Members
- 160.00K
- weixing tian
- Independent Directors, Audit Committee Member
- 160.00K
- qian jiang
- Board Secretary, Deputy General Manager
- 884.90K
- wang xu
- Securities Affairs Representative
- --
- xiaolong luo
- Chairman of the Supervisory Board, Auditors
- --
- ru li
- Auditors
- --
- zongbin yu
- General Manager
- 1.02M
- haiyan cui
- Deputy General Manager
- 884.90K
- shisui luo
- Deputy General Manager
- 1.02M
- liwen tan
- Deputy General Manager
- 884.90K
- kang chen
- Deputy General Manager
- 1.01M
- yonghong yuan
- Executive Deputy General Manager
- 2.68M
- zunyi liu
- Chief Financial Officer
- --
- yan feng
- Chief Economist
- 380.90K
- tingmei xu
- Employee Supervisors
- 94.80K
- yan li
- Employee Supervisors
- 34.50K
- qilin hu
- Employee Supervisors
- 35.00K
Analysis
Price Target
No Data
No Data